SciBX: Science-Business eXchange Contents: November 8 2012, Volume 5 / Issue 44

TABLE OF CONTENTS November 8 2012, Volume 5 / Issue 44 Analysis Cover Story Translational Notes Tools The Distillery: Therapeutics Cancer Endocrine/metabolic disease Hematology Infectious disease Inflammation Neurology The Distillery: Techniques Assays and screens Chemistry Disease models Drug platforms Markers New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Turning lupus against cancer Lauren Martz doi:10.1038/scibx.2012.1151 Researchers at Yale have found that a lupus-related autoantibody sensitizes cancer cells to DNA-damaging radiation and chemotherapy. The antibody, which has already proven safe in a clinical trial in SLE, may be effective as a monotherapy for patients with BRCA-mutant cancers. Full Text | PDF Translational Notes Top Animal instincts Tim Fulmer doi:10.1038/scibx.2012.1152 A workshop convened by the NINDS has proposed a set of standards for designing and reporting on animal studies. The challenges will be to implement the standards throughout the research community and determine which preclinical studies should adhere to them. Full Text | PDF Tools Top MuSIC by design Tracey Baas doi:10.1038/scibx.2012.1153 A Harvard Medical School and Tsinghua University team has developed a technology, dubbed MuSIC, that identifies synergistic drug pairs. The group showed proof of concept by finding new combinations of therapeutics for HIV, but weeding out false negatives is a challenge. Full Text | PDF IBD's bacteria cafeteria Kai-Jye Lou doi:10.1038/scibx.2012.1154 French researchers have engineered food-grade lactic acid bacteria that secrete the protease inhibitor elafin, a promising therapeutic for intestinal inflammation. Oral delivery of the engineered bacteria reduced inflammation and restored intestinal homeostasis in mouse models of inflammatory bowel disease. Full Text | PDF Distillery: Therapeutics Cancer Top β-Catenin (CTNNB1) doi:10.1038/scibx.2012.1155 In vitro and cell culture studies identified a CTNNB1 antagonist that could help treat wingless-type MMTV integration site (WNT) and CTNNB1–driven cancers. Full Text | PDF Not applicable doi:10.1038/scibx.2012.1156 Mouse studies suggest oncolytic viruses could help prevent cancer metastasis following surgery. Full Text | PDF MicroRNA-23b (miR-23b) doi:10.1038/scibx.2012.1157 Patient sample and mouse studies suggest increasing miR-23b signaling could help treat prostate cancer. Full Text | PDF Endocrine/metabolic disease Top Serotonin; tryptophan hydroxylase 1 (TPH1; TPH) doi:10.1038/scibx.2012.1158 Mouse studies suggest inhibiting synthesis of gut-derived serotonin through TPH1 could help treat type 2 diabetes. Full Text | PDF Lacto-N-fucopentaose III (LNFPIII) doi:10.1038/scibx.2012.1159 In vitro and mouse studies suggest LNFPIII could help treat metabolic diseases. Full Text | PDF Hematology Top E selectin (SELE; CD62E) doi:10.1038/scibx.2012.1160 Mouse studies suggest blocking SELE could help prevent neutropenia during chemotherapy or radiation therapy. Full Text | PDF Infectious disease Top Protein kinase B (PKB; PKBA; AKT; AKT1); phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2012.1161 In vitro studies suggest inhibiting the PI3K and AKT pathway could help prevent HCV infection. Full Text | PDF Unknown doi:10.1038/scibx.2012.1162 In vitro studies identified two fluoroalkylated γ-lactams derived from 4-aminoquinoline that could help treat malaria. Full Text | PDF Inflammation Top Bromodomain containing 4 (BRD4); IL-6 doi:10.1038/scibx.2012.1163 In vitro and rodent studies identified BRD4 inhibitors that could help treat inflammation. Full Text | PDF Neurology Top Solute carrier family 25 member 38 (SLC25A38); β-amyloid 42 doi:10.1038/scibx.2012.1164 Human and rodent studies suggest inhibiting SLC25A38 could prevent neurodegeneration in AD. Full Text | PDF Potassium channel KCa2.2 (KCNN2); KCNN3; ataxin 2 (ATXN2; SCA2) doi:10.1038/scibx.2012.1165 Mouse studies suggest positive allosteric modulators (PAMs) of KCNN2 could help treat spinocerebellar ataxia type 2. Full Text | PDF IL-1 receptor doi:10.1038/scibx.2012.1166 Rat studies suggest antagonizing IL-1 receptor in the brain could help prevent postoperative cognitive dysfunction in older individuals. Full Text | PDF Purinergic receptor P2X ligand-gated ion channel 4 (P2RX4) doi:10.1038/scibx.2012.1167 An SAR study identified P2RX4 antagonists that could be useful for treating neuropathic pain and SCI. Full Text | PDF Distillery: Techniques Assays and screens Top Androgen receptor (AR) activation levels on circulating tumor cells (CTCs) to predict response to second-line therapy in castration-resistant prostate cancer (CRPC) doi:10.1038/scibx.2012.1168 In vitro studies suggest AR activation on CTCs could help prostate cancer prognosis. Full Text | PDF Fluorescent sensor for γ-aminobutyric acid (GABA) and GABA receptor ligands doi:10.1038/scibx.2012.1169 A fluorescent sensor could be useful for measuring concentrations of GABA and GABA receptor ligands on the cell surface. Full Text | PDF Chemistry Top Synthesis of xanthofulvin and vinaxanthone doi:10.1038/scibx.2012.1170 A method to synthesize the natural compounds xanthofulvin and vinaxanthone could help their development in spinal cord injury (SCI). Full Text | PDF Disease models Top NADPH oxidase 2 (Nox2)-deficient, lupus-prone mice doi:10.1038/scibx.2012.1171 Nox2-deficient, lupus-prone mice could be useful models for severe systemic lupus erythematosus (SLE). Full Text | PDF Transgenic rats expressing full-length huntingtin (HTT) as a model for Huntington's disease (HD) doi:10.1038/scibx.2012.1172 Transgenic rats that express full-length HTT could help identify new HD therapies. Full Text | PDF Xenograft mouse model for pediatric acute megakaryoblastic leukemia (AMKL) doi:10.1038/scibx.2012.1173 A mouse xenograft model for pediatric AMKL could help identify new treatments for the cancer. Full Text | PDF Drug platforms Top Elafin-secreting lactic acid bacteria for treating inflammatory bowel disease (IBD) doi:10.1038/scibx.2012.1174 Elafin-secreting lactic acid bacteria could be useful for treating IBD. Full Text | PDF Markers Top Taste receptor type 2 member 38 (TAS2R38) genotyping for Gram-negative bacterial infection susceptibility doi:10.1038/scibx.2012.1175 In vitro studies suggest TAS2R38 genotyping could help determine treatment regimens for Gram-negative bacterial infections. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.